Lisa H. Butterfield, PhD
Vice President, PICI Research Center, Parker Institute for Cancer Immunotherapy
Adjunct Professor, Microbiology and Immunology, University of California San Francisco
Lisa H. Butterfield, Ph.D., is Vice President of the PICI Research Center, Parker Institute for Cancer Immunotherapy and Adjunct Professor of Microbiology and Immunology at the University of California San Francisco. Previously, she was Professor of Medicine, Surgery, Immunology and Clinical and Translational Science at the University of Pittsburgh and Director of the Immunologic Monitoring and Cellular Products Laboratory (IMCPL) at the UPMC Hillman Cancer Center. She obtained her PhD in Biology at UCLA, followed by postdoctoral fellowships in Cellular Immunology and Cancer Gene Therapy also at UCLA. She is the President of the Society of Immunotherapy of Cancer (SITC, 2016-2018), and on the SITC Immune Biomarkers Task Force Steering Committee, after serving on several committees, as Secretary/Treasurer and Vice President. She is a member of AAI and AACR and serves on committees and participates in educational efforts for those societies. Dr. Butterfield also serves as Director of the ECOG-ACRIN National Clinical Trials Network Immunology Reference Laboratory, as well as Melanoma Committee Lab Liaison and on the Immune Biomarkers Committee. She investigates immunotherapy and cancer vaccines for hepatocellular cancer and for melanoma, involving peptides, dendritic cells and adenoviruses, and effector responses to tumor antigens. As Associate Director (2005-2010) and Director of the IMCPL (2010-present), she oversees the cellular product clinical trial production for multiple trials and multiple types of products involving dendritic cells, NK cells and T cells. She also develops and standardizes immunotherapy biomarker assays for clinical trials. Dr. Butterfield has published over 140 peer-reviewed manuscripts, reviews and book chapters, taught at the University of Pittsburgh, and has mentored over 20 postdocs and students.